Huron Consulting Group Inc. · NASDAQ:HURN
Huron Consulting — Conference Presentation (July 2022)
36 slides from Huron Consulting's conference presentation, July 2022

Slide 1: Preparing for Success: CCSG Clinical Protocol & Data Management Review
PREPARING FOR SUCCESS CCSG CLINICAL PROTOCOL & DATA MANAGEMENT REVIEW

Slide 2: Preparing for Success: CCSG Clinical Protocol & Data Management Review
Preparing for Success: CCSG Clinical Protocol & Data Management Review 1. Introductions & Information 2. Clinical Protocol & Data Management 3. Site Visit Preparation & Other Helpful Tips 4. Site Perspective 5. Q&A 2

Slide 3: Introductions & Information
1 INTRODUCTIONS & INFORMATION

Slide 4: Today's Moderator
TODAY’S MODERATOR + 25 years of health care and cancer center experience + Director, Research Administration - Georgetown University, Lombardi Comprehensive Cancer Center + Certified Research Administrator + Interim director of clinical trials office for NCI-designated center ELLEN MCLAUGHLIN + Over

Slide 5: Today's Presenters
Today’s Presenters • 27 years of clinical research and cancer center experience • Associate Director, Administration – Medical University of South Carolina, Hollings Cancer Center – Washington University, Siteman Cancer Center • Clinical Trials Administrator ANITA L. HARRISON DIRECTOR – UCSF T 843-8

Slide 6: Today's Presenters
Today’s Presenters • 22 years of progressive clinical research management roles in industry and academia • Administrative Director, Clinical Trials Office – Medical University of South Carolina, Hollings Cancer Center – Multiple interim directorships for TERRI L. MATSON emerging NCI-designated cente

Slide 7: Ask Us Your Questions Through the Chat Feature
Ask Us Your Questions Through the Chat Feature Enter a question in this dialog area at any time 7

Slide 8: Types of Cancer Centers Represented Today
Types of Cancer Centers Represented Today 11% 50% 39% NCI-designated comprehensive cancer center Aspiring NCI-designated cancer center NCI-designated cancer center 8

Slide 9: Previous CPDM Merit Rating of Participating Centers
Previous CPDM Merit Rating of Participating Centers 12% 15% 41% 32% Do not know Not a current NCI-designated cancer center Exceptional to outstanding Excellent to very good 9

Slide 10: Disclaimer
Disclaimer The material presented today is based upon our current understanding of the Cancer Center Support Grant funding opportunity announcement (FOA) as outlined in PAR-17-095. https://grants.nih.gov/grants/guide/pa-files/PAR-17-095.html 10

Slide 11: Terminology
Terminology Terms Definition CPDM Clinical Protocol and Data Management. Centers often rename their CPDM functional unit as “CTO”, “CRO”, “CRS”, “CTSU” CCSG Cancer Center Support Grant CTMS Clinical Trials Management System CTRP Clinical Trials Reporting Program DSM, DSMC, Data and Safety Monitoring

Slide 12: Resources
Resources • Office of Cancer Centers Webpage – https://cancercenters.cancer.gov/GrantsFunding/GrantsFunding • CCSG Funding Opportunity Announcement • Data and Safety Monitoring Plan examples • Data Table Guides • Listing of Approved Peer Review Funding Organizations – https://cancercenters.cancer.go

Slide 13: Clinical Protocol & Data Management
2 CLINICAL PROTOCOL & DATA MANAGEMENT

Slide 14: Typical Cancer Center Clinical Research Infrastructure
Typical Cancer Center Clinical Research Infrastructure Associate Director of Clinical Research Clinical Research Leadership Committee Clinical Trials Office Clinical Working Protocol Review Data & Safety (CPDM) Groups Committee Monitoring Operational Feasibility Protocol Review & Assessment M onitor

Slide 15: Expectations of the CTO/CPDM
Expectations of the CTO/CPDM • Provides central management and oversight functions for coordinating, facilitating, and reporting on cancer-relevant clinical studies for the institutions that define the center • Serves as the central location of all cancer protocols and maintains a centralized databa

Slide 16: CPDM Written Section
CPDM Written Section Required Attachments Budget/Justification Abstract Specific Aims Research Strategy Part I. CPDM Part II. Data and Safety Monitoring Part III. Inclusion of Women and Minorities Part IV. Inclusion of Children in Clinical Research 16

Slide 17: Sample Format Attachment
Sample Format Attachment ACCRUAL TO CLINICAL RESEARCH STUDIES 2013-2017 Table 1. ACCRUAL TO ALL INTERVENTIONAL CLINICAL RESEARCH STUDIES 2013-2017 Calendar Year 2013 2014 2015 2016 2017 National Group 114 137 125 135 114 External Peer Review 7,737 6,335 416 1,469 508 Institutional (investigator-init

Slide 18: Sample Format Attachment 2A
Sample Format Attachment 2A INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH Table 4. Demographics - Cancer Incidence in CENTER’S Catchment Area & Cancer Patient Population Demographics for Demographics for Newly Diagnosed CENTER Persons Newly Cancer Patients at Catchment Area Diagnosed with C

Slide 19: Sample Format Attachment 2B
Sample Format Attachment 2B INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH Table 5. Accrual to CENTER Clinical Research Studies (2017) Interventional Interventional Non-Interventional Treatment Non-Treatment Accrual Accrual Accrual (N=1,625) (N=573) (N=531) Gender Male 288 50% 229 43% 610 38

Slide 20: CPDM Budget/Justification
CPDM Budget/Justification • Appropriate Cost Inclusions: – CTO medical and administrative leadership effort – CTO staff positions that speed protocol preparation, revision, and activation: – Dedicated trial activation staff – Staff within the legal and/or contracting office devoted to negotiating Ce

Slide 21: CPDM Budget/Justification
CPDM Budget/Justification Centers may consider including a table demonstrating the breakdown of the CPDM budget Clinical Trials Office Budget and CCSG Request Income Source CCSG Year 05 Percent of Total Proposed Proposed Percent (FY18) CCSG Year 06 of Total (FY19) CCSG $300,379 2% $419,576 3% Instit

Slide 22: CPDM Abstract & Specific Aims
CPDM Abstract & Specific Aims • Abstract – Limit: 30 lines – Summary of Parts I-IV • Specific Aims – Limit: 1 page – Include aims for Parts I-IV 22

Slide 23: CPDM Written Section
CPDM Written Section Required Attachments Budget/Justification Abstract Specific Aims Research Strategy (12 pages) Part I. CPDM (~8 pgs) Part II. Data and Safety Monitoring (~2 pgs) Part III. Inclusion of Women and Minorities (~1-1.5 pgs) Part IV. Inclusion of Children in Clinical Research (~0.5 pg)

Slide 24: Typical Content Part I. CPDM
Typical Content Part I. CPDM • CPDM achievements during CCSG project period (or last 3 years for new centers) • Itemized response to previous CCSG reviewer critiques • Characterization of the Center’s clinical research activity, examples may include (utilize impactful graphics): – Reduced time to st

Slide 25: Typical Content Part I. CPDM
Typical Content Part I. CPDM • Organization and Management Structure – Include organization chart outlining functional units within CTO including FTE counts – Characterize each functional unit – Describe qualifications and responsibilities of CTO medical director and administrator • Services – Regul

Slide 26: Typical Content Part I. CPDM
Typical Content Part I. CPDM • Environment – CTO location(s) – IT capabilities (e.g., CTMS, eRegulatory, EDC) • Policies – Standard operating procedures – Research billing compliance – Data and safety monitoring • Governance, Oversight, Strategic Planning, and Evaluation – Describe relevant Center l

Slide 27: CPDM Review Criteria
CPDM Review Criteria 1. How effective is CPDM in centralizing, managing, and reporting on the cancer clinical trials of the Center? 2. How effective are the quality control functions and training services offered by the CPDM? 3. Does the CPDM successfully identify impediments to successful accrual o

Slide 28: Typical Content Part II. DSM
Typical Content Part II. DSM • This section summarizes (~2 pages) the formal DSMP, including the DSMC that is charged with overseeing all Center-driven IIS, which should be submitted and approved (reapproved) prior to CCSG submission • DSM will be the focus of a future Huron webinar 28

Slide 29: Typical Content Parts III & IV. Women, Minorities, & Children
Typical Content Parts III & IV. Women, Minorities, & Children • These sections summarize (~1.5-2 pgs) data presented in the 2A & 2B attachments • Area(s) with deficiencies need to have a detailed plan outlined • Inclusion of Minorities, Women, and Children will be the focus of a future Huron webinar

Slide 30: Site Visit Preparation & Other Helpful Tips
3 SITE VISIT PREPARATION & OTHER HELPFUL TIPS

Slide 31: Site Visit (4-6 Months Post Submission)
Site Visit (4-6 Months Post Submission) • Meet with Center leaders to confirm site visit agenda and time allotments – CPDM presentation typically 10 min with 10 min Q&A; presented by CTO Medical Director or Associate Director of Clinical Research – CPDM may be presented in combination with PRMS, DSM

Slide 32: Site Visit (4-6 Months Post Submission)
Site Visit (4-6 Months Post Submission) • Centers often include CTO poster • Have available biosketches for PRMS, DSMC, and CTO leadership; SOPs; and supporting materials demonstrating CPDM services (e.g., IT solution demonstration, external communications) • Updated clinical research data including

Slide 33: Q&A
Q&A

Slide 34: Contact Us
Contact Us ANITA L. HARRISON TERRI L. MATSON DIRECTOR MANAGER T 843-801-5045 T 843-810-6871 E aharrison@huronconsultinggroup.com E tmatson@huronconsultinggroup.com ELLEN MCLAUGHLIN DIRECTOR T 703-559-0067 E emclaughlin@huronconsultinggroup.com 34

Slide 35: Future Thought Leadership Opportunities
Future Thought Leadership Opportunities • Data and Safety Monitoring • Protocol Review and Monitoring System • Inclusion of Minorities, Women, and Children in Clinical Research • Data Tables 3 & 4 Subscribe to our email list for the most up-to-date webinars, news alerts and thought leadership on thi

Slide 36: Thank You!
THANK YOU!
Source: Internet Archive copy of huronconsultinggroup.com
More decks from Huron Consulting Group Inc.
Investor Presentation (July 2026)49 slides · July 2026
Investor Presentation (March 2026)49 slides · March 2026
Q4 2025 Earnings Presentation12 slides · Feb 24, 2026
Investor Presentation (July 2025)44 slides · July 2025
Shareholder Meeting (March 2025)13 slides · Mar 28, 2025
Investor Day (March 2025)77 slides · Mar 25, 2025